In pancreatic ductal adenocarcinoma (PDAC), elevated IL-2 levels are associated with better prognosis and enhanced antitumor immunity, and that IL-2-based co-culture with human peripheral blood mononuclear cells (PBMCs) significantly improves dendritic cell (DC) tumor infiltration and T-cell activation, providing a promising strategy to optimize DC-based immunotherapy for PDAC (14). Here, IL2 is linked to pancreatic ductal adenocarcinoma.